The newest FDA-approved medication for overactive bladder (OAB) is vibegron, sold under the brand name Gemtesa. It belongs to a class called beta-3 adrenergic agonists, which work differently from the older anticholinergic drugs that have been the standard treatment for decades. Vibegron represents a significant shift in how OAB is treated, driven largely by growing safety concerns about those older medications.
How Vibegron Works
Vibegron relaxes the bladder muscle during filling by activating beta-3 receptors on the bladder wall. When these receptors are switched on, the muscle that squeezes the bladder loosens up, increasing bladder capacity so you can hold more urine comfortably and feel fewer sudden urges to go.
This is fundamentally different from older OAB drugs like oxybutynin, tolterodine, and solifenacin. Those medications are anticholinergics, which block a different signaling pathway to calm the bladder. The problem is that this pathway also operates in the brain, the gut, the eyes, and the salivary glands, which is why anticholinergics are notorious for side effects like dry mouth, constipation, blurred vision, and cognitive fog. Beta-3 agonists sidestep most of those issues because the receptors they target are concentrated in the bladder rather than spread throughout the body.
What the Clinical Trials Showed
Vibegron’s approval was based on the EMPOWUR trial, a 12-week study comparing 75 mg of vibegron daily against a placebo. The results showed meaningful improvements across the core symptoms of OAB. Women taking vibegron reduced their daily bathroom trips by an average of 1.9 times, compared to 1.4 for placebo. Urgency episodes dropped by 2.8 per day versus 1.9 with placebo. And for the symptom that often disrupts life the most, urgency urinary incontinence (leaking before you can get to a bathroom), vibegron cut episodes by 2.1 per day compared to 1.4 with placebo.
Those differences may sound modest in absolute numbers, but for someone dealing with 8 or more urgency episodes a day, shaving off nearly 3 of them can mean the difference between dreading a car ride and feeling comfortable leaving the house.
Why Doctors Are Moving Away From Older OAB Drugs
The shift toward beta-3 agonists like vibegron isn’t just about convenience or fewer nuisance side effects. It’s about brain health. A growing body of research has linked long-term anticholinergic use to increased risk of dementia and Alzheimer’s disease, particularly in older adults.
One large prospective study of over 3,400 participants found that people in the highest exposure group (equivalent to taking oxybutynin 5 mg daily for more than three years) had a 54% increased risk of dementia and a 63% increased risk of Alzheimer’s disease compared to non-users. Another study tracking the cognitive status of anticholinergic users found they were nearly 2.5 times more likely to progress to mild cognitive impairment or Alzheimer’s. This risk was greatest with the most potent anticholinergic drugs.
A more recent study directly compared the two drug classes, following over 47,000 new anticholinergic users and nearly 24,000 new beta-3 agonist users. Anticholinergic users had a 23% higher risk of developing dementia. Based on this evidence, the American Urogynecologic Society now recommends avoiding anticholinergic OAB medications entirely in women over 70.
Side Effects of Vibegron
Vibegron’s side effect profile is relatively mild. In the pivotal trial, the most common reactions were headache (4% vs. 2.4% with placebo), upper respiratory symptoms like a runny nose or sore throat (2.8% vs. 1.7%), and diarrhea (2.2% vs. 1.1%). Notably absent from that list: the dry mouth that plagues anticholinergic users and drives many of them to stop treatment.
One advantage vibegron has over anticholinergics is a lower risk of urinary retention, the inability to fully empty your bladder. Anticholinergics carry a specific warning about this risk, especially in people with bladder outlet obstruction. Beta-3 agonists work through a different mechanism that is less likely to cause this problem.
How to Take It
Vibegron comes as a single 75 mg tablet taken once daily, with or without food. You can swallow it whole with water, or if swallowing pills is difficult, crush it and mix it with about a tablespoon of applesauce, then take it immediately with a glass of water. There’s no need to time it around meals or take multiple doses throughout the day.
Where Vibegron Fits in Treatment Guidelines
The most recent guidelines from the American Urological Association and the Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction have made a notable change: they no longer recommend a rigid step-by-step treatment ladder. Previously, patients were typically expected to try behavioral strategies first, then move to medication, then consider more invasive options only if drugs failed.
The updated approach groups treatments into categories and emphasizes shared decision-making. You and your provider choose the best option based on your symptoms, preferences, and tolerance for potential side effects, rather than being required to fail one treatment before trying another. Within the medication category, beta-3 agonists like vibegron and mirabegron (Myrbetriq, approved earlier) are recommended alongside anticholinergics as equally valid first choices, with strong evidence supporting their use for reducing urgency, frequency, and incontinence episodes.
In practice, many providers now lean toward beta-3 agonists as the preferred starting medication, especially for older patients, given the dementia risk associated with anticholinergics. Mirabegron was the first beta-3 agonist to reach the market, and vibegron is the newer addition to this class. Both target the same receptor, giving patients and providers a second option if one doesn’t work well or causes side effects.